Navigation Links
ULURU Inc. Announces First Order Of Altrazeal For European Launch
Date:9/20/2012

ADDISON, Texas, Sept. 20, 2012 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR), announced today the receipt of the first European order for the launch of Altrazeal® in Austria.

It is anticipated that Altrazeal® will be launched in Austria in October. Over the past 12 months Altrazeal® has been extensively clinically evaluated at the major wound care centers in Vienna by key opinion leaders. These evaluations have demonstrated the clinical benefits of Altrazeal® in chronic wounds and very importantly the potential to generate significant cost savings for the health care system.

Commenting on the launch of Altrazeal® in Austria, Helmut Kerschbaumer, Chairman of Melmed Holdings AG, stated, "We have conducted extensive pre-marketing activities to generate the necessary key opinion leader support not only in Austria but throughout Europe. The clinical and economic advantages that have been demonstrated are significant benefits that make Altrazeal® a unique product in the wound care market. Also, its ability to inhibit bacterial growth over an extended period when used with different antiseptics is considered a major marketing opportunity. The properties of Altrazeal® including extended wear time, reduced wound care provider treatment time and clinical outcomes make it an ideal product for the European market."

In addition to the activities in Austria there are ongoing programs throughout Europe designed to prepare for the launch of Altrazeal® in additional markets in early 2013. An advisory group with key opinion leaders from all major European countries has been assembled to assist and direct activities to position Altrazeal® for market success. Clinical programs are being developed to clearly demonstrate the economic advantages generated by the use of Altrazeal®

Kerry Gray, President and
'/>"/>

SOURCE ULURU Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ULURU Inc. Reports Second Quarter 2012 Financial Results
2. ULURU Inc. Announces Completion Of $2.2mil Convertible Debt Offering
3. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
4. FDAnews announces Third Annual Pharmaceutical Labeling Summit
5. CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $6 Billion of Common Stock
6. PRN Physician Recommended Nutriceuticals announces partnership with Dr. Eric Donnenfeld and expansion in the New York City metropolitan area
7. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
8. Specialty Pharmacy Certification Board Announces Inaugural Board of Directors
9. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
10. Golden Meditech Holdings Limited Announces Updates on Medical Devices Subsidiary Latest Development
11. Active Life Announces Launch of Next Generation BioDentTM for Life Science Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... IRVINE, Calif. , Oct 22, 2014 ... Irvine, California , announced the receipt ... Small Business Innovation Research award (SBIR) from the National Institute of ... will fund the development of a Pan-HIV Protein Microarray ... the HIV-1 and HIV-2 subtypes and aid in the ...
(Date:10/22/2014)... Oct. 22, 2014  Paper Pak Industries, a ... APLS ® Body Guard Bio, a disposable, ... of bacteria and virus while protecting service providers ... Bio features a rugged, external nylon shell, watertight ... a leak-proof inner chamber that contains contaminated and ...
(Date:10/22/2014)... , Oct. 22, 2014  With a ... animal health medications, a Global Pharmaceutical and Biotech ... serialization technology and turnkey solution to protect their ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... that was serialized and aggregated by the Xyntek ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... 30 Shire plc (LSE: SHP, ... announced findings at a major medical meeting from a Phase ... Daytrana ® (methylphenidate transdermal system) in adolescents aged 13 ... ). In addition, data regarding the pharmacokinetic profile ...
... , SAN DIEGO, Oct. 30 Gen-Probe Incorporated (Nasdaq: ... the Oppenheimer 20th Annual Healthcare Conference in New York on ... at the Lazard Capital Markets 6th Annual Healthcare Conference in ... Eastern time. The presentations are scheduled to be webcast ...
Cached Medicine Technology:Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 2Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 3Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 4Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 5Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 6Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 7Gen-Probe to Webcast Two Upcoming Investor Presentations 2
(Date:10/22/2014)... 22, 2014 Isabel Healthcare ... Health Professions (ASAHP) Conference on October 22-24 in Las ... participate in a panel discussion on Technology in Health ... Healthcare provides a diagnostic decision support tool and clinical ... skills of students and clinical learners. The Isabel tools ...
(Date:10/22/2014)... 2014 The Louis W. ... dedicated to distribute health information technology innovation to ... announced the development of six key guiding principles ... receiving healthcare. These are an expansion of the ... care that is respectful of and responsive to ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a ... of bacterial infections, microbial biofilms, and chronic wounds, announced ... of directors. , Dr. Sinskey is ... Massachusetts Institute of Technology, or MIT. He has been ... Sinskey also holds positions as Co-Director of the Malaysia-MIT ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. ... in vitro fertilization (IVF) -- the incubation of embryos in ... device inside the vagina, new research suggests. Scientists from ... an INVOcell, might sharply cut costs for pricey IVF procedures ... accessible to those who don,t live near big-city assisted reproduction ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... Dendreon Corporation (Nasdaq:,DNDN) will release its third quarter financial ... conference call at 1:30,p.m. PT; 4:30 p.m. ET to review ... discussion may be obtained as follows: Time: ... November 15, 2007 Dial-in: ...
... 17th U.S. Surgeon General Richard H. Carmona Joins ... Says Report Findings May Open,Doors to Positive Change, ... and Prevent (STOP) Obesity Alliance today received a ... obesity in America:,unrealistic definitions of success, negative perceptions ...
... ARLINGTON, Va., Nov. 2 FBR Capital Markets,Corporation ... that,Christopher Warren has joined FBR Capital Markets as a ... group and will,focus on the medical device sector. ... research, and we,value the disciplined, rigorous method he,s developed ...
... dexamethasone contributes to a relentless fatigue and poor quality ... leukemia (ALL), according to a new study from St. ... could improve the quality of life for these children ... or eliminate these side effects. , The St. ...
... ... Options, WASHINGTON, Nov. 2 Today, the Society ... interventional cardiology, announced the,launch of Seconds Count, a patient ... authoritative resource about cardiovascular disease and,treatment. The program will ...
... Duane Reade Holdings, Inc. today,announced that on Thursday, November ... results before the open of the market. In ... conference,call on Thursday, November 8, 2007 at 10:00 a.m. ... Officer, and John Henry,Senior Vice President and Chief Financial ...
Cached Medicine News:Health News:-Dendreon to Hold Conference Call on Thursday, November 15, 2007 at 4:30 PM ET- 2Health News:New Academic Analysis Identifies Three Barriers to Achieving Healthy and Achievable Policies to Combat Obesity in America 2Health News:New Academic Analysis Identifies Three Barriers to Achieving Healthy and Achievable Policies to Combat Obesity in America 3Health News:FBR Capital Markets Hires Senior Healthcare Analyst 2Health News:St. Jude finds anti-leukemia drug increases patient fatigue 2Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 2Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 3
Provides extended cold therapy to the shoulder area for acute, chronic, or post-surgical applications. The DuraKold products can help reduce pain, edema, and speed recovery....
Provides continuous cold therapy to the knee area for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and facilitate faster rehabilitation....
... Halo™ was designed in 1988 as an attachment ... patient, it greatly restricts rotation of the cervical ... Halo can be removed while allowing the Collar ... used in conjunction with the Philadelphia Stabilizer attachment., ...
... cold therapy Gel Pad. Our Gel Pad helps ... to reduce swelling and /or hot therapy to ... order hot and cold therapy gel pad, place ... suspenders can be added to each support upon ...
Medicine Products: